• Cleveland BioLabs Inc., of Buffalo, N.Y., said results of the first structural and biophysical study of Toll-like receptor 5 (TLR5)/flagellin interaction help to decipher the molecular mechanisms underlying TLR5 recognition and signaling by CBLB502, an optimized derivative of bacterial flagellin and the company's candidate in development as a radiation countermeasure and a cancer therapeutic agent.